SEC Form 4 · accession 0001288123-17-000021
AGENUS INC · AGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garo H Armen
Officer — Chairman & CEO
Period of report
Apr 19, 2017
Accepted (ET)
Apr 21, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001098972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 19, 2017 | A | 71,964 | $3.39 | A | 1,490,441 | D | |
| Common StockF2 | holding | — | — | — | 4,046 | I | By Antigenics Holdings |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents settlement of vested restricted shares granted on July 1, 2015.
- F2Dr. Armen is Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership to the extent of his pecuniary interest therein.